Cipla Limited — Ritonavir Exporter Profile
Indian Pharmaceutical Exporter · #3 for Ritonavir · $1.4M export value · DGFT Verified
Cipla Limited is the #3 Indian exporter of Ritonavir with $1.4M in export value and 28 verified shipments. Cipla Limited holds a 1.8% market share in Ritonavir exports across 10 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Ritonavir Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Ritonavir?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $245.1K | 7 | 24.4% |
| VIETNAM, DEMOCRATIC REP. OF | $200.0K | 4 | 19.9% |
| VIETNAM | $189.6K | 4 | 18.9% |
| VIETNAM DEMOCRATIC REP. OF | $100.0K | 2 | 10.0% |
| LIBYA | $100.0K | 2 | 10.0% |
| MOROCCO | $50.0K | 1 | 5.0% |
| UNITED STATES | $50.0K | 1 | 5.0% |
| ALGERIA | $34.5K | 1 | 3.4% |
| PUERTO RICO | $23.0K | 2 | 2.3% |
| FRANCE | $8.5K | 1 | 0.8% |
Cipla Limited exports Ritonavir to 12 countries. The largest destination is SOUTH AFRICA accounting for 24.4% of Cipla Limited's Ritonavir shipments, followed by VIETNAM, DEMOCRATIC REP. OF (19.9%) and VIETNAM (18.9%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ritonavir from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MEDPRO PHARMACEUTICA (PTY) LTD, | SOUTH AFRICA | $150.0K | 3 |
| CENTRAL PHARMACEUTICAL CPC1. JSC | VIETNAM, DEMOCRATIC REP. OF | $100.0K | 2 |
| CENTRAL PHARMACEUTICAL CPC1.JSC | VIETNAM, DEMOCRATIC REP. OF | $100.0K | 2 |
| CENTRAL PHARMACEUTICALCPC1JSC(CPC1) | VIETNAM | $100.0K | 2 |
| TO THE ORDER OF | LIBYA | $100.0K | 2 |
| CENTRAL PHARMACEUTICAL | VIETNAM | $89.6K | 2 |
| MEDPRO PHARMACEUTICA (PTY) LTD.. | SOUTH AFRICA | $68.8K | 3 |
| MINISTRE DE LA SANT DIRECTION DE | MOROCCO | $50.0K | 1 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $50.0K | 1 |
| CENTRAL PHARMACEUTICAL CPC1. | VIETNAM DEMOCRATIC REP. OF | $50.0K | 1 |
Cipla Limited supplies Ritonavir to 17 buyers globally. The largest buyer is MEDPRO PHARMACEUTICA (PTY) LTD, (SOUTH AFRICA), followed by CENTRAL PHARMACEUTICAL CPC1. JSC (VIETNAM, DEMOCRATIC REP. OF) and CENTRAL PHARMACEUTICAL CPC1.JSC (VIETNAM, DEMOCRATIC REP. OF). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ritonavir Export Value and How Much Does Cipla Limited Contribute?
India exported $69.2M worth of Ritonavir through 1,555 shipments from 84 suppliers to 155 countries, serving 525 buyers globally. Cipla Limited contributes $1.4M to this total, accounting for 1.8% of India's Ritonavir exports. Cipla Limited ships Ritonavir to 12 countries through 17 buyers.
What Is the Average Shipment Value for Cipla Limited's Ritonavir Exports?
Cipla Limited's average Ritonavir shipment value is $50.0K per consignment, based on 28 shipments totaling $1.4M. The largest destination is SOUTH AFRICA (24.4% of Cipla Limited's Ritonavir exports).
How Does Cipla Limited Compare to Other Indian Ritonavir Exporters?
Cipla Limited ranks #3 among 84 Indian Ritonavir exporters with a 1.8% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($27.5M), HETERO LABS LIMITED ($24.7M), EMCURE PHARMACEUTICALS LIMITED ($5.5M). Cipla Limited processed 28 shipments to 10 destination countries.
What Ritonavir Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LOPINAVIR / RITONAVIR ORAL PELLETS 40MG/ | $50.0K | 1 |
| RITONAVIR TABLETS USP 100 MG 31920 PACK X1X30S 957600 NOS | $50.0K | 1 |
| LOPIMUNE 200/50MG TABLETS (LOPINAVIR 200MG+RITONAVIR 50MG) (1995 PACK X 1X120'S=239400 NOS) | $50.0K | 1 |
| LOPIMUNE 200/50MG TABLETS (LOPINAVIR 200MG+RITONAVIR 50MG) (1965 PACK X 1X120'S=235800 NOS) | $50.0K | 1 |
| LOPIMUNE 200/50MG TABLETS (LOPINAVIR 200MG+RITONAVIR 50MG) (1920 PACKX1X120'S=230400 NOS) | $50.0K | 1 |
| LOPIMUNE 200/50MG TABLETS (LOPINAVIR 200MG+RITONAVIR 50MG) (1725 PACKX1X120'S=207000 NOS) | $50.0K | 1 |
| TARITO 300/100 TABLET (ATAZANAVIR 300MG+ RITONAVIR 100MG) (4798 PACKS X 1X30S=143940 NOS) | $50.0K | 1 |
| TARITO 300/100 TABLET (ATAZANAVIR 300MG+ RITONAVIR 100MG) (4771 PACKS X 1X30S=143130 NOS) | $50.0K | 1 |
| TARITO 300/100 TABLET (ATAZANAVIR 300MG+ RITONAVIR 100MG) (4726 PACKS X 1X30S=141780 NOS) | $50.0K | 1 |
| LOPIMUNE 200/50MG TABLETS (LOPINAVIR 200MG+RITONAVIR 50MG)(2370 PACKS X1X120S=284400 NOS) | $50.0K | 1 |
Cipla Limited exports 27 distinct Ritonavir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LOPINAVIR / RITONAVIR ORAL PELLETS 40MG/ with 1 shipments worth $50.0K.
Regulatory Requirements: Exporting Ritonavir to Key Markets
What Cipla Limited must comply with to export Ritonavir to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Ritonavir Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | AUROBINDO PHARMA LIMITED | $2.1M | 43 | 26 | $50.0K |
| 8 | MACLEODS PHARMACEUTICALS LTD | $1.8M | 36 | 11 | $50.0K |
| 3 | CIPLA LIMITED ★ | $1.4M | 28 | 10 | $50.0K |
| 6 | EMCURE PHARMACEUTICALS LTD | $400.0K | 8 | 7 | $50.0K |
| 10 | GLOBELA PHARMA PRIVATE LIMITED | $276.5K | 13 | 2 | $21.3K |
Cipla Limited ranks #3 among 84 Indian Ritonavir exporters. Average shipment value of $50.0K compared to the market average of $823.4K. The closest competitors by value are AUROBINDO PHARMA LIMITED and MACLEODS PHARMACEUTICALS LTD.
Which Indian Ports Ship Ritonavir Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 335 | 21.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 281 | 18.1% |
| HYDERABAD ACC (INHYD4) | 217 | 14.0% |
| HYDERABAD AIR | 123 | 7.9% |
| Bombay Air | 87 | 5.6% |
| NHAVA SHEVA SEA (INNSA1) | 58 | 3.7% |
| DELHI AIR CARGO ACC (INDEL4) | 48 | 3.1% |
| HYDERABAD ICD | 47 | 3.0% |
Geopolitical & Trade Policy Impact on Cipla Limited's Ritonavir Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Ritonavir, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ritonavir — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ritonavir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 28 individual customs records matching Cipla Limited exporting Ritonavir, covering 27 formulations to 12 countries via 17 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 155+ countries, 525+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ritonavir Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Ritonavir exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Ritonavir Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ritonavir. For current shipment-level data, contact TransData Nexus.